prospan 35 mg/5 ml sīrups
engelhard arzneimittel gmbh & co.kg, germany - vijīgās efejas lapu sausais ekstrakts - sīrups - 7 mg/ml
pregagamma 25 mg cietās kapsulas
wörwag pharma gmbh & co.kg, germany - pregabalīns - cietās kapsulas - 25 mg
pregagamma 75 mg cietās kapsulas
wörwag pharma gmbh & co.kg, germany - pregabalīns - kapsula, cietā - 75 mg
pregagamma 150 mg cietās kapsulas
wörwag pharma gmbh & co.kg, germany - pregabalīns - kapsula, cietā - 150 mg
bosentan welding 62,5 mg apvalkotās tabletes
welding gmbh & co.kg, germany - bosentāns - apvalkotās tabletes - 62,5 mg
bosentan welding 125 mg apvalkotās tabletes
welding gmbh & co.kg, germany - bosentāns - apvalkotās tabletes - 125 mg
recombinate 500 sv/5 ml pulveris un šķīdinātājs injekciju šķīduma pagatavošanai
baxalta innovations gmbh, austria - oktokogs, alfa - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 500 sv/5 ml
recombinate 1000 sv/5 ml pulveris un šķīdinātājs injekciju šķīduma pagatavošanai
baxalta innovations gmbh, austria - oktokogs, alfa - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 1000 sv/5 ml
recombinate 250 sv/5 ml pulveris un šķīdinātājs injekciju šķīduma pagatavošanai
baxalta innovations gmbh, austria - oktokogs, alfa - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 250 sv/5 ml
ultomiris
alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.